Expression of the nonclassical HLA class I and MICA/B molecules in human hepatocellular carcinoma

Neoplasma

Volumn 58, Issue 5, 2011, Pages 371-376

  Chen, A ^a   Shen, Y ^a   Xia, M ^a   Xu, L ^a   Pan, N ^a   Yin, Y ^a   Miao, F ^a   Shen, C ^a   Xie, W ^a   Zhang, J ^a  

^a MEDICAL SCHOOL OF SOUTHEAST UNIVERSITY   (China)

Author keywords

Hepatocellular carcinoma; HLA E; HLA G; MICA; MICB

Indexed keywords

HLA A ANTIGEN; HLA B ANTIGEN; HLA E ANTIGEN; HLA G ANTIGEN; MESSENGER RNA; HLA ANTIGEN; HLA ANTIGEN CLASS 1; HLA-E ANTIGEN; HLA-G ANTIGEN; MHC CLASS I RELATED CHAIN A; MHC CLASS I-RELATED CHAIN A; MICB ANTIGEN;

ADULT; ANTIGEN EXPRESSION; ARTICLE; CANCER TISSUE; CLINICAL ARTICLE; DOWN REGULATION; FEMALE; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; MALE; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING; GENE EXPRESSION REGULATION; GENETICS; LIVER TUMOR; METABOLISM; MIDDLE AGED; PHYSIOLOGY; PROGNOSIS;

BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTOCOMPATIBILITY ANTIGENS CLASS I; HLA ANTIGENS; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 80052930294     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: 10.4149/neo_2011_05_371     Document Type: Article

References (31)

1. LE BOUTEILLER P. HLA class I chromosomal region, genes, and products: facts and questions. Cri Rev Immunol 1994:14:89-129.
2. LE BOUTEILLER P, BLASCHITZ A. The functionality of HLA-G is emerging. Immunol Rev 1999:167:233-44. doi:10.1111/j.1600-065X.1999.tb01396.x.
3. ROUAS-FREISS N, MOREAU P, FERRONE S, CAROSELLA ED. HLA-G proteins in cancer: do they provide tumor cells with an escape mechanism? Cancer Res 2005:65:10139-44. doi:10.1158/0008-5472.CAN-05-0097.
4. PAUL P, Rouas-Freiss N, Khalil-Daher I, MOREAU P, RITEAU B, et al. HLA-G expression in melanoma: a way for tumor cells to escape from immunosurveillance. Proc Natl Acad Sci U S A. 1998:95:4510-5. doi:10.1073/pnas.95.8.4510.
5. RITEAU B, MENIER C, khalill-daher I, MARTINOZZI S, PLA M, et al. HLA-G1 co-expression boosts the HLA class I-mediated NK lysis inhibition. Int Immunol. 2001:13:193-201. doi:10.1093/intimm/13.2.193.
6. MILLER, J.D., D.A. WEBER, C. IBEGBU, J. POHL, J.D. ALTMAN, JENSE PE. Analysis of HLA-E peptide-binding specificity and contact residues in bound peptide required for recognition by CD94/NKG2. J Immunol 2003:171:1369-1375.
7. BORREGO F, ULBRECHT M, WEISS EH, COLIGAN JE, BROOKS AG. Recognition of human histocompatibility leukocyte antigen (HLA)-E complexed with HLA class I signal sequence-derived peptides by CD94/NKG2 confers protection from natural killer cell-mediated lysis. J Exp Med 1998: 187: 813-818. doi:10.1084/jem.187.5.813.
8. BAHRAM S, BRESNAHA M, GERAGHTY DE, SPIES T. A second lineage of mammalian major histocompatibility complex class I genes. Proc Natl Acad Sci U S A. 1994: 91: 6259-63. doi:10.1073/pnas.91.14.6259.
9. HENRY AFS. MICA and MICB genes: can the enigma of their polymorphism be resolved? Trends Immunol 2001: 22: 378-85. doi:10.1016/S1471-4906(01)01960-3.
10. BAUER S, GROH V, WU J, STEINLE A, PHILLIPS JH, et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 1999: 285: 727-9. doi:10.1126/science.285.5428.727.
11. CURRY MP, NORRIS S, Golden-Mason L, DOHERTY DG, DEIGNAN T, et al. Isolation of lymphocytes from normal adult human liver suitable for phenotypic and functional characterization. J Immunol Methods. 2000: 242: 21-31. doi:10.1016/S0022-1759(00)00204-0.
12. TAKETOMI A, SHIMADA M, SHIRABE K, KAJIYAMA K, GION T, et al. Natural killer cell activity in patients with hepatocellular carcinoma: a new prognostic indicator after hepatectomy. Cancer 1998: 83: 58-63. doi:10.1002/(SICI)1097-0142(19980701)83:1<58::AID-CNCR8>3.0.CO;2-A.
13. KAWARABAYASHI N, SEKI S, HATSUSE K, OHKAWA T, KOIKE Y, et al. Decrease of CD56(+)T cells and natural killer cells in cirrhotic livers with hepatitis C may be involved in their susceptibility to hepatocellular carcinoma. Hepatology. 2000: 32: 962-9. doi:10.1053/jhep.2000.19362.
14. SMYTH MJ, THIA KY, STREET SE, CRETNEY E, TRAPANI et al. Differential tumor surveillance by natural killer (NK) and NKT cells. J Exp Med. 2000: 191: 661-8. doi:10.1084/ jem.191.4.661.
15. Kim S, Iizuka K, AGUILA HL, WEISMAN IL, YOKOYAMA WM. In vivo natural killer cell activities revealed by natural killer cell-deficient mice. Proc Natl Acad Sci U S A. 2000: 97: 2731-6. doi:10.1073/pnas.050588297.
16. JINUSHI M, TAKEHARA T, TATSUMI T, KANTO T, GROH V, et al. Expression and role of MICA and MICB in human hepatocellular carcinomas and their regulation by retinoic acid. Int J Cancer. 2003: 104: 354-61. doi:10.1002/ijc.10966.
17. CAI MY, XU YF, QIU SJ, JU MJ, GAO Q, et al. Human leukocyte antigen-G protein expression is an unfavorable prognostic predictor of hepatocellular carcinoma following curative resection. Clin Cancer Res. 2009:15: 4686-93. doi:10.1158/1078-0432.CCR-09-0463.
18. DRAKE CG, JAFFEE E, PARDOLL DM. Mechanisms of immune evasion by tumors. Adv Immunol. 2006: 90:51-81. doi:10.1016/S0065-2776(06)90002-9.
19. FERRONE S, MARINCOLA FM. Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. Immunol Today. 1995: 16: 487-94. doi:10.1016/0167-5699(95)80033-6.
20. WISCHHUSEN J, WASCHBISCH A, WIENDL H. Immune-refractory cancers and their little helpers-an extended role for immunetolerogenic MHC molecules HLA-G and HLA-E? Semin Cancer Bio 2007: 17: 459-68. doi:10.1016/j.semcancer.2007.07.005.
21. YOU J, SRIPLUNG H, CHONGSUVIVATWONG V, GEATER A, ZUANG L, et al. Profile, spectrum and significance of hepatitis B virus genotypes in chronic HBV-infected patients in Yunnan, China. Hepatobiliary Pancreat Dis Int 2008: 7: 271-9.
22. SHEN Y, XIA M, ZHANG J, XU L, YANG J, et al. IRF-1 and p65 mediate upregulation of constitutive HLA-A antigen expression by hepatocellular carcinoma cells. Mol Immunol. 2009: 46: 2045-53. doi:10.1016/j.molimm.2009.03.001.
23. UROSEVIC M, KURRER MO, KAMARASHEV J, MUELLER B, WEDER W, et al. Human leukocyte antigen G up-regulation in lung cancer associates with high-grade histology, human leukocyte antigen class I loss and interleukin-10 production. Am J Pathol. 2001: 159: 817-24. doi:10.1016/S0002-9440(10)61756-7.
24. BUKUR J, REBMANN V, Grosse-Wilde H, LUBOLDT H, RUEBBEN H, et al. Functional role of human leukocyte antigen-G up-regulation in renal cell carcinoma. Cancer Res. 2003: 63: 4107-11.
25. YIE SM, YANG H, YE SR, LI K, DONG DD, et al. Expression of HLA-G is associated with prognosis in esophageal squamous cell carcinoma. Am J Clin Pathol. 2007: 128: 1002-9. doi:10.1309/JNCW1QLDFB6AM9WE.
26. YIE SM, YANG H, YE SR, LI K, DONG DD et al. Expression of human leukocyte antigen G (HLA-G) correlates with poor prognosis in gastric carcinoma. Ann Surg Oncol. 2007: 14: 2721-9. doi:10.1245/s10434-007-9464-y.
27. WIENDL H, MITSDOERFFER M, HOFMEISTER V, WISCHHUSEN J, BORNEMANN A, et al. A functional role of HLA-G expression in human gliomas: an alternative strategy of immune escape. J Immunol. 2002: 168: 4772-80.
28. CHEN Y, CHENG M, TIAN Z. Hepatitis B virus down-regulates expressions of MHC class I molecules on hepatoplastoma cell line. Cell Mol Immunol. 2006: 3: 373-8.
29. Stern-Ginossar N, GUR C, BITON M, HORWITZ E, ELBOIM et al. Human microRNAs regulate stress-induced immune responses mediated by the receptor NKG2D. Nat Immunol 2008;9:1065-73. doi:10.1038/ni.1642.
30. Rodriguez-Rodero S, GONZALEZ S, RODRIGO L, Fernandez-Morera JL, Martinez-Borraj, et al. Transcriptional regulation of MICA and MICB: a novel polymorphism in MICB promoter alters transcriptional regulation by Sp1. Eur J Immuno. 2007: 37: 1938-53. doi:10.1002/eji.200737031.
31. GOBIN SJ, VAN DEN ELSENl PJ. Locus-specific regulation of HLA-A and HLA-B expression is not determined by nucleotide variation in the X2 box promoter element. Blood 2001: 97: 1518-21. doi:10.1182/blood.V97.5.1518.